26 related articles for article (PubMed ID: 38758553)
1. Measuring the Influence of Side Effect Expectations, Beliefs, and Incident Side Effects on the Risk for Drug Discontinuation Among Individuals Starting New Medications, a Cross-sectional Study.
Blackburn DF; Yao S; Taylor JG; Alefan Q; Lix LM; Eurich DT; Choudhry NK
Patient Prefer Adherence; 2024; 18():979-989. PubMed ID: 38774475
[TBL] [Abstract][Full Text] [Related]
2. Dynamic Projection of Medication Nonpersistence and Nonadherence Among Patients With Early Breast Cancer.
Rinder P; Marcille T; Sinel-Boucher P; Cals-Maurette M; Kanoun D; Levy C; Teixeira L; Hornus P; Szeftel D; Heudel PE
JAMA Netw Open; 2024 May; 7(5):e2411909. PubMed ID: 38758553
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of CDK4/6 inhibitors combined with endocrine therapy versus endocrine therapy alone in hormone receptor-positive, HER2-negative, advanced breast cancer: a systematic review and meta-analysis.
Dai Q; Wang Y; Liao M; Chen H
Ann Palliat Med; 2022 Dec; 11(12):3727-3742. PubMed ID: 36635998
[TBL] [Abstract][Full Text] [Related]
4. Medication delivery factors and adjuvant endocrine therapy adherence in breast cancer.
Neuner JM; Fergestrom N; Pezzin LE; Laud PW; Ruddy KJ; Winn AN
Breast Cancer Res Treat; 2023 Jan; 197(1):223-233. PubMed ID: 36357711
[TBL] [Abstract][Full Text] [Related]
5. Contribution of cost to treatment nonadherence in the US breast cancer survivors: a population-based analysis.
Zheng C; Chagpar AB
Breast Cancer Res Treat; 2022 Apr; 192(2):369-373. PubMed ID: 34988768
[TBL] [Abstract][Full Text] [Related]
6. Evidence-based approaches for the management of side-effects of adjuvant endocrine therapy in patients with breast cancer.
Franzoi MA; Agostinetto E; Perachino M; Del Mastro L; de Azambuja E; Vaz-Luis I; Partridge AH; Lambertini M
Lancet Oncol; 2021 Jul; 22(7):e303-e313. PubMed ID: 33891888
[TBL] [Abstract][Full Text] [Related]
7. Five-Year Adjuvant Endocrine Therapy Adherence Trajectories Among Women With Breast Cancer: A Nationwide French Study Using Administrative Data.
Lailler G; Memoli V; Le Bihan Benjamin C; Ben Diane MK; Lauzier S; Mancini J; Bousquet PJ; Bouhnik AD
Clin Breast Cancer; 2021 Aug; 21(4):e415-e426. PubMed ID: 33745868
[TBL] [Abstract][Full Text] [Related]
8. Serum Detection of Nonadherence to Adjuvant Tamoxifen and Breast Cancer Recurrence Risk.
Pistilli B; Paci A; Ferreira AR; Di Meglio A; Poinsignon V; Bardet A; Menvielle G; Dumas A; Pinto S; Dauchy S; Fasse L; Cottu PH; Lerebours F; Coutant C; Lesur A; Tredan O; Soulie P; Vanlemmens L; Jouannaud C; Levy C; Everhard S; Arveux P; Martin AL; Dima A; Lin NU; Partridge AH; Delaloge S; Michiels S; André F; Vaz-Luis I
J Clin Oncol; 2020 Aug; 38(24):2762-2772. PubMed ID: 32568632
[TBL] [Abstract][Full Text] [Related]
9. Seasonal adherence to, and effectiveness of, subcutaneous interferon β-1a administered by RebiSmart® in patients with relapsing multiple sclerosis: results of the 1-year, observational GEPAT-SMART study.
Deftereos SN; Koutlas E; Koutsouraki E; Kyritsis A; Papathanassopoulos P; Fakas N; Tsimourtou V; Vlaikidis N; Tavernarakis A; Voumvourakis K; Arvanitis M; Sakellariou D; DeLorenzo F
BMC Neurol; 2018 Nov; 18(1):186. PubMed ID: 30400884
[TBL] [Abstract][Full Text] [Related]
10. French administrative health care database (SNDS): The value of its enrichment.
Scailteux LM; Droitcourt C; Balusson F; Nowak E; Kerbrat S; Dupuy A; Drezen E; Happe A; Oger E
Therapie; 2019 Apr; 74(2):215-223. PubMed ID: 30392702
[TBL] [Abstract][Full Text] [Related]
11. Prevalence and associated factors of medication non-adherence in hematological-oncological patients in their home situation.
Bouwman L; Eeltink CM; Visser O; Janssen JJWM; Maaskant JM
BMC Cancer; 2017 Nov; 17(1):739. PubMed ID: 29121889
[TBL] [Abstract][Full Text] [Related]
12. Breast cancer oral anti-cancer medication adherence: a systematic review of psychosocial motivators and barriers.
Lin C; Clark R; Tu P; Bosworth HB; Zullig LL
Breast Cancer Res Treat; 2017 Sep; 165(2):247-260. PubMed ID: 28573448
[TBL] [Abstract][Full Text] [Related]
13. Factors Associated with Adherence to Adjuvant Endocrine Therapy Among Privately Insured and Newly Diagnosed Breast Cancer Patients: A Quantile Regression Analysis.
Farias AJ; Hansen RN; Zeliadt SB; Ornelas IJ; Li CI; Thompson B
J Manag Care Spec Pharm; 2016 Aug; 22(8):969-78. PubMed ID: 27459660
[TBL] [Abstract][Full Text] [Related]
14. Contributors to nonadherence and nonpersistence with endocrine therapy in breast cancer survivors recruited from an online research registry.
Stanton AL; Petrie KJ; Partridge AH
Breast Cancer Res Treat; 2014 Jun; 145(2):525-34. PubMed ID: 24781972
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic compliance of first line disease-modifying therapies in patients with multiple sclerosis. COMPLIANCE Study.
Saiz A; Mora S; Blanco J;
Neurologia; 2015 May; 30(4):214-22. PubMed ID: 24484756
[TBL] [Abstract][Full Text] [Related]
16. Factors influencing adherence to cancer treatment in older adults with cancer: a systematic review.
Puts MTE; Tu HA; Tourangeau A; Howell D; Fitch M; Springall E; Alibhai SMH
Ann Oncol; 2014 Mar; 25(3):564-577. PubMed ID: 24285020
[TBL] [Abstract][Full Text] [Related]
17. Use of tamoxifen before and during pregnancy.
Braems G; Denys H; De Wever O; Cocquyt V; Van den Broecke R
Oncologist; 2011; 16(11):1547-51. PubMed ID: 22020212
[TBL] [Abstract][Full Text] [Related]
18. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients.
Hershman DL; Kushi LH; Shao T; Buono D; Kershenbaum A; Tsai WY; Fehrenbacher L; Gomez SL; Miles S; Neugut AI
J Clin Oncol; 2010 Sep; 28(27):4120-8. PubMed ID: 20585090
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
